JP2017536102A5 - - Google Patents

Download PDF

Info

Publication number: JP2017536102A5
Authority: JP; Japan
Prior art keywords: antibody; hvr; disease; synuclein; amino acid
Prior art date: 2015-10-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2017520354A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017536102A (ja

Filing date

2015-10-15

Publication date

2018-11-22

2015-10-15 Application filed filed Critical

2015-10-15 Priority claimed from PCT/US2015/055796 external-priority patent/WO2016061389A2/en

2017-12-07 Publication of JP2017536102A publication Critical patent/JP2017536102A/ja

2018-11-22 Publication of JP2017536102A5 publication Critical patent/JP2017536102A5/ja

Status Pending legal-status Critical Current

Links

125000003275 alpha amino acid group Chemical group 0.000 claims 32
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 20
208000009829 Lewy Body Disease Diseases 0.000 claims 20
201000002832 Lewy body dementia Diseases 0.000 claims 20
208000018737 Parkinson disease Diseases 0.000 claims 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 12
206010003591 Ataxia Diseases 0.000 claims 10
206010012289 Dementia Diseases 0.000 claims 10
208000001089 Multiple system atrophy Diseases 0.000 claims 10
206010033799 Paralysis Diseases 0.000 claims 10
102000019355 Synuclein Human genes 0.000 claims 10
108050006783 Synuclein Proteins 0.000 claims 10
230000002567 autonomic effect Effects 0.000 claims 10
210000004556 brain Anatomy 0.000 claims 10
230000008021 deposition Effects 0.000 claims 10
201000010099 disease Diseases 0.000 claims 10
208000035475 disorder Diseases 0.000 claims 10
229910052742 iron Inorganic materials 0.000 claims 10
210000005036 nerve Anatomy 0.000 claims 10
208000021090 palsy Diseases 0.000 claims 10
208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 10
230000009885 systemic effect Effects 0.000 claims 10
102000003802 alpha-Synuclein Human genes 0.000 claims 9
108090000185 alpha-Synuclein Proteins 0.000 claims 9
239000003814 drug Substances 0.000 claims 8
230000004770 neurodegeneration Effects 0.000 claims 6
125000000539 amino acid group Chemical group 0.000 claims 4
208000015122 neurodegenerative disease Diseases 0.000 claims 4
230000000626 neurodegenerative effect Effects 0.000 claims 4
238000000034 method Methods 0.000 claims 3
150000007523 nucleic acids Chemical class 0.000 claims 3
102000039446 nucleic acids Human genes 0.000 claims 3
108020004707 nucleic acids Proteins 0.000 claims 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
210000004027 cell Anatomy 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
239000000825 pharmaceutical preparation Substances 0.000 claims 2
238000012258 culturing Methods 0.000 claims 1

JP2017520354A 2014-10-16 2015-10-15 抗アルファ−シヌクレイン抗体及び使用方法 Pending JP2017536102A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462064867P	2014-10-16	2014-10-16
US62/064,867		2014-10-16
PCT/US2015/055796 WO2016061389A2 (en)	2014-10-16	2015-10-15	Anti-alpha-synuclein antibodies and methods of use

Publications (2)

Publication Number	Publication Date
JP2017536102A JP2017536102A (ja)	2017-12-07
JP2017536102A5 true JP2017536102A5 (2)	2018-11-22

Family

ID=54356660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017520354A Pending JP2017536102A (ja)	2014-10-16	2015-10-15	抗アルファ−シヌクレイン抗体及び使用方法

Country Status (5)

Country	Link
US (2)	US9732148B2 (2)
EP (1)	EP3207057A2 (2)
JP (1)	JP2017536102A (2)
CN (1)	CN107074938A (2)
WO (1)	WO2016061389A2 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201512203D0 (en)	2015-07-13	2015-08-19	Lundbeck & Co As H	Agents,uses and methods
AR110074A1 (es)	2016-11-15	2019-02-20	H Lundbeck As	Agentes, usos y métodos para el tratamiento de la sinucleinopatía
CN110072888B (zh)	2016-12-16	2023-07-18	H.隆德贝克有限公司	药剂、用途和方法
US10364286B2 (en)	2016-12-22	2019-07-30	H. Lundbeck A/S	Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3049110A1 (en) *	2017-01-06	2018-07-12	Abl Bio Inc.	Anti-.alpha.-syn antibody and use thereof
US12049493B2 (en)	2017-01-06	2024-07-30	Abl Bio Inc.	Anti-alpha-synuclein antibodies and uses thereof
CN110506057B (zh)	2017-02-17	2023-09-29	百时美施贵宝公司	Alpha突触核蛋白抗体及其应用
WO2018237338A1 (en) *	2017-06-23	2018-12-27	Denali Therapeutics Inc.	Anti-alpha-synuclein antibodies and methods of use thereof
US20190153102A1 (en) *	2017-09-28	2019-05-23	Prothena Biosciences Limited	Dosing regimes for treatment of synucleinopathies
US12071483B1 (en) *	2017-12-14	2024-08-27	Abl Bio Inc.	Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
CA3096222A1 (en)	2018-04-06	2019-10-10	Atyr Pharma, Inc.	Compositions and methods comprising anti-nrp2 antibodies
WO2020009482A1 (ko) *	2018-07-03	2020-01-09	에이비엘바이오 주식회사	항 알파-시누클레인 항체 및 그 용도
TWI734279B (zh) *	2018-12-14	2021-07-21	美商美國禮來大藥廠	抗α-突觸核蛋白抗體及其用途
CN110172098B (zh) *	2019-05-27	2023-03-10	长春工业大学	抗α-突触核蛋白的单克隆抗体及其应用
KR102444797B1 (ko) *	2019-06-14	2022-09-20	에이비엘바이오 주식회사	α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CN114746120B (zh) *	2019-10-03	2024-07-30	Atyr医药公司	包含抗nrp2抗体的组合物和方法
CA3159964A1 (en) *	2019-12-04	2021-06-10	Ac Immune Sa	Novel molecules for therapy and diagnosis
EP4229082A1 (en) *	2020-10-16	2023-08-23	AC Immune SA	Antibodies binding to alpha-synuclein for therapy and diagnosis
CN113912713B (zh) *	2021-12-15	2022-03-08	北京凯祥弘康生物科技有限公司	一种抗α-突触核蛋白的单克隆抗体及其应用
CN114853887B (zh) *	2022-03-08	2022-12-20	骏蓦(北京)生物科技有限公司	一种特异性结合α-突触核蛋白的抗体及其应用
WO2025158162A1 (en) *	2024-01-25	2025-07-31	Imperial College Innovations Limited	Alpha-synuclein antibody
GB202408492D0 (en) *	2024-06-13	2024-07-31	Nd Biosciences Sa	Anti-alpha-synuclein antibody
CN120064410A (zh) *	2025-04-28	2025-05-30	协和生物制药（天津）有限公司	一种用于α-突触核蛋白检测的电化学生物传感器

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en)	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
WO1993006217A1 (en)	1991-09-19	1993-04-01	Genentech, Inc.	EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
AU675929B2 (en)	1992-02-06	1997-02-27	Curis, Inc.	Biosynthetic binding protein for cancer marker
MD1367C2 (ro)	1992-11-13	2000-11-30	Idec Pharmaceuticals Corporation	Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
AU691811B2 (en)	1993-06-16	1998-05-28	Celltech Therapeutics Limited	Antibodies
WO1995006407A1 (en)	1993-08-30	1995-03-09	The Regents Of The University Of California	Novel component of amyloid in alzheimer's disease and methods for use of same
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en)	1994-11-03	1998-08-04	Genentech, Inc.	Process for bacterial production of polypeptides
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5840523A (en)	1995-03-01	1998-11-24	Genetech, Inc.	Methods and compositions for secretion of heterologous polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
ATE296315T1 (de)	1997-06-24	2005-06-15	Genentech Inc	Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en)	1998-08-11	2000-03-21	North Caroline State University	Genetically engineered duckweed
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ES2375931T3 (es)	1997-12-05	2012-03-07	The Scripps Research Institute	Humanización de anticuerpo murino.
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
ES2292236T3 (es)	1998-04-02	2008-03-01	Genentech, Inc.	Variantes de anticuerpos y sus fragmentos.
ES2434961T5 (es)	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu)	1999-01-15	2018-03-28	Genentech Inc.	Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1176195B1 (en)	1999-04-09	2013-05-22	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US7125978B1 (en)	1999-10-04	2006-10-24	Medicago Inc.	Promoter for regulating expression of foreign genes
CN100427603C (zh)	1999-10-04	2008-10-22	麦迪卡格公司	调控外源基因转录的方法
CA2388245C (en)	1999-10-19	2012-01-10	Kyowa Kirin Co., Ltd.	The use of serum-free adapted rat cells for producing heterologous polypeptides
AU784983B2 (en)	1999-12-15	2006-08-17	Genentech Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ATE344801T1 (de)	1999-12-29	2006-11-15	Immunogen Inc	Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
CN101289511A (zh)	2000-04-11	2008-10-22	杰南技术公司	多价抗体及其应用
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
ES2639222T5 (es)	2000-10-06	2023-11-24	Kyowa Kirin Co Ltd	Células que producen unas composiciones de anticuerpo
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CN1487996B (zh)	2000-11-30	2010-06-16	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
EP2180044A1 (en)	2001-08-03	2010-04-28	GlycArt Biotechnology AG	Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en)	2001-10-25	2011-03-28	Genentech Inc	Glycoprotein compositions
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US20040132140A1 (en)	2002-04-09	2004-07-08	Kyowa Hakko Kogyo Co., Ltd.	Production process for antibody composition
EA200401325A1 (ru)	2002-04-09	2005-04-28	Киова Хакко Когио Ко., Лтд.	Клетки с модифицированным геномом
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4832719B2 (ja)	2002-04-09	2011-12-07	協和発酵キリン株式会社	ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
ATE503829T1 (de)	2002-04-09	2011-04-15	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
EP1513879B1 (en)	2002-06-03	2018-08-22	Genentech, Inc.	Synthetic antibody phage libraries
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
EP3263596A1 (en)	2002-12-16	2018-01-03	Genentech, Inc.	Immunoglobulin variants and uses thereof
CA2510003A1 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
SI1633189T1 (sl)	2003-05-19	2017-12-29	Prothena Biosciences Limited	Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
JPWO2005035778A1 (ja)	2003-10-09	2006-12-21	協和醗酵工業株式会社	α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
ES2672640T3 (es)	2003-11-05	2018-06-15	Roche Glycart Ag	Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7498298B2 (en)	2003-11-06	2009-03-03	Seattle Genetics, Inc.	Monomethylvaline compounds capable of conjugation to ligands
WO2005047860A2 (en)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Antibodies to alpha-synuclein
WO2005053742A1 (ja)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	抗体組成物を含有する医薬
CN1961003B (zh)	2004-03-31	2013-03-27	健泰科生物技术公司	人源化抗TGF-β抗体
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
KR100891620B1 (ko)	2004-04-13	2009-04-02	에프. 호프만-라 로슈 아게	항-ｐ-셀렉틴 항체
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
KR101270829B1 (ko)	2004-09-23	2013-06-07	제넨테크, 인크.	시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
CA2657953A1 (en)	2005-07-19	2007-01-25	University Of Rochester	Alpha-synuclein antibodies and methods related thereto
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en)	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
JP2009536527A (ja)	2006-05-09	2009-10-15	ジェネンテック・インコーポレーテッド	最適化されたスキャフォールドを備えた結合ポリペプチド
WO2008027236A2 (en)	2006-08-30	2008-03-06	Genentech, Inc.	Multispecific antibodies
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
PL2118300T3 (pl)	2007-02-23	2015-11-30	Prothena Biosciences Ltd	Zapobieganie i leczenie synukleinopatii i amyloidozy
PT2132230E (pt) *	2007-03-22	2014-07-17	Genentech Inc	Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
CA2701788C (en) *	2007-10-05	2017-06-13	Genentech, Inc.	Humanized beta-amyloid antibody for treating ocular diseases
ES2563027T3 (es)	2008-01-07	2016-03-10	Amgen Inc.	Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
HUE031944T2 (en) *	2008-02-08	2017-08-28	Immunas Pharma Inc	Antibodies capable of specific binding of amyloid β-oligomers and their use
PT2282758T (pt)	2008-04-29	2019-02-12	Bioarctic Ab	Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
AU2009328505B2 (en) *	2008-12-19	2014-11-27	Panima Pharmaceuticals Ag	Human anti-alpha-synuclein autoantibodies
US8609097B2 (en) *	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2624835T3 (es) *	2009-08-06	2017-07-17	Immunas Pharma, Inc.	Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
JP5599454B2 (ja) *	2009-08-06	2014-10-01	イムナス・ファーマ株式会社	Ａβオリゴマーに特異的に結合する抗体およびその利用
CN102597233B (zh) *	2009-08-07	2014-10-29	协和发酵麒麟株式会社	人源化抗淀粉样-b寡聚体抗体
CA2789963C (en)	2010-02-26	2019-09-03	Bioarctic Neuroscience Ab	Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en)	2010-03-03	2011-09-21	Dr. Rentschler Holding GmbH & Co. KG	Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
WO2012051498A2 (en)	2010-10-15	2012-04-19	The Board Of Regents Of The University Of Texas System	Antibodies that bind amyloid oligomers
HUE041391T2 (hu)	2011-06-23	2019-05-28	Biogen Int Neuroscience Gmbh	Anti-alfa-szinukleinkötõ molekulák
US8609820B2 (en)	2011-10-28	2013-12-17	Neotope Biosciences Limited	Humanized antibodies that recognize alpha-synuclein
US20140295465A1 (en)	2011-11-02	2014-10-02	Biogen Idec International Neuroscience Gmbh	USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
NZ629296A (en)	2012-01-27	2016-06-24	Prothena Biosciences Ltd	Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) *	2013-02-28	2017-01-03	United Arab Emirates University	Alpha-synuclein antibodies and uses thereof

2015
- 2015-10-15 US US14/884,542 patent/US9732148B2/en not_active Expired - Fee Related
- 2015-10-15 EP EP15785211.2A patent/EP3207057A2/en not_active Withdrawn
- 2015-10-15 JP JP2017520354A patent/JP2017536102A/ja active Pending
- 2015-10-15 WO PCT/US2015/055796 patent/WO2016061389A2/en not_active Ceased
- 2015-10-15 CN CN201580050881.0A patent/CN107074938A/zh active Pending
2017
- 2017-07-07 US US15/644,007 patent/US20170320940A1/en not_active Abandoned

Publication	Publication Date	Title
JP2017536102A5 (2)	2018-11-22
JP2015533795A5 (2)	2016-11-04
RU2015143886A (ru)	2017-04-28	Антитела к тау и способы применения
JP2020500538A5 (2)	2021-11-11
JP2016063812A5 (2)	2016-10-13
PH12018500708A1 (en)	2018-10-15	Humanized anti-human cd19 antibodies and methods of use
JP2010526028A5 (2)	2011-04-07
RU2017119543A (ru)	2018-12-06	Анти-tim3 антитела и способы их применения
JP2018519810A5 (2)	2019-11-28
JP2013538553A5 (2)	2014-06-19
JP2018521638A5 (2)	2019-07-11
HRP20221141T1 (hr)	2022-11-25	Anti-lag3 protutijela
RU2017125758A (ru)	2019-01-22	Антитела к с5 и способы их применения
JP2016512551A5 (2)	2017-04-06
HRP20231134T1 (hr)	2024-01-05	Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
JP2019513701A5 (2)	2020-04-16
JP2013520984A5 (2)	2014-04-24
JP2019528083A5 (2)	2020-07-30
JP2013198490A5 (2)	2013-11-21
HRP20201493T1 (hr)	2020-12-11	Anti-alfa-sinukleinska protutijela i postupci uporabe
JP2015510510A5 (2)	2016-03-24
RU2013102225A (ru)	2014-07-27	АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2014526898A5 (2)	2015-03-26
JP2018108086A5 (2)	2018-10-25
JP2019522961A5 (2)	2020-05-14